相关实验视频

Updated: Jun 4, 2025

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

基于CDK2的CDK7模仿作为结构分析的工具:生物化学验证和晶体结构与SY56099

Jana Škerlová¹, Veronika Krejčiříková¹, Miroslav Peřina²

¹Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.

International journal of biological macromolecules

|December 29, 2024

概括

研究人员设计了修改后的CDK2蛋白CDK2m7,以模仿CDK7. 这种新的工具促进了基于结构的药物设计,用于开发用于癌症治疗的新CDK7抑制剂.

科学领域:

生物化学生物化学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

循环素依赖激酶 (CDK) 是细胞循环和转录的关键调节者.
CDK7对于细胞分裂和增殖至关重要,其基因变异在癌症中很常见.
针对CDK7治疗是一种有前途的癌症策略,但基于结构的药物设计是有限的.

研究的目的:

开发一种新的蛋白质模拟CDK7,使结构辅助药物设计成为可能.
为开发CDK7抑制剂创建一个可靠和可扩展的平台.

主要方法:

CDK2活性部位的突变,以创建一个CDK7模仿物 (CDK2m7).
在大肠杆菌中产生活性CDK2m7-环素A2复合物.
用CDK7抑制剂 (SY5609) 结晶CDK2m7进行结构分析.

主要成果:

CDK2m7以高产量和纯度生产,与环林A2.2形成一个活性复合体.
与CDK2.2.7相比,CDK2m7显示出一种转向CDK7的抑制剂选择性,与CDK2.2相比.
确定了与SY5609复合的CDK2m7的晶体结构,展示了它的实用性.

结论:

CDK2m7作为一个有效和负担得起的平台,以结构为基础的合理药物开发,以CDK7.7为目标.
这种模仿促进了用于癌症治疗的新型CDK7抑制剂的设计.

关键词:

循环素依赖的激酶酶.抑制剂的抑制剂在SY5609中,您可以使用SY5609.选择性的选择性结构辅助抑制剂设计结构辅助抑制剂设计在X射线晶体学.

更多相关视频

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...